Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced BRAF-mutant Cancers 1

Interventions

Vemurafenib 1PX-866 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced BRAF-mutant Cancers × PX-866 × Clear all
NCT01616199 2018-05-16

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Seagen Inc.

Phase 1/2 Terminated
24 enrolled

Advanced BRAF-mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡